Premium
Adeno‐associated virus‐mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model
Author(s) -
Yoo Jinsang,
Choi Seeyoung,
Hwang KyungSun,
Cho WonKyung,
Jung ChoRok,
Kwon SukTae,
Im DongSoo
Publication year - 2006
Publication title -
the journal of gene medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.689
H-Index - 91
eISSN - 1521-2254
pISSN - 1099-498X
DOI - 10.1002/jgm.832
Subject(s) - tumor necrosis factor alpha , genetic enhancement , transfection , adeno associated virus , cancer research , apoptosis , microbiology and biotechnology , gene delivery , biology , in vivo , cell culture , medicine , chemistry , immunology , recombinant dna , vector (molecular biology) , gene , biochemistry , genetics
Background Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) induces cell death in various tumor cells, but relatively spares normal cells. Recombinant adeno‐associated virus (rAAV) vectors have a number of advantages including in vivo long‐term gene expression. Here, we assessed the biological activity of a novel, secreted form of TRAIL (sTRAIL) for cancer gene therapy using a rAAV2 vector. Methods A plasmid and rAAV2 vectors were constructed encoding sTRAIL composed of a leader sequence, the isoleucine zipper, and the active domain of TRAIL (aa 95–281). The functionality of sTRAIL was validated by cell viability, FACS analysis, caspase‐3 activity, and TUNEL staining. rAAV‐sTRAIL was injected intratumorally to nude mice bearing human A549 lung tumor cells. Nude mice received A549 tumor cells after intravenous delivery of rAAV‐sTRAIL. The antitumor effect was then evaluated by measuring tumor regression and occurrence in the experimental animal. Results sTRAIL was released from cells transfected with the sTRAIL expression construct or transduced with rAAV‐sTRAIL, and induced apoptosis in cancer cells, but spared normal fibroblast cells. Secreted sTRAIL formed oligomers including trimers with intersubunit disulfide. Purified sTRAIL exerted much lower cytotoxicity on primary human hepatocytes compared to recombinant TRAIL. Intratumoral delivery of rAAV‐sTRAIL significantly inhibited growth of A549 tumors established in nude mice. A number of apoptotic tumor cells were detected by TUNEL staining in mice treated with rAAV‐sTRAIL. Systemic pretreatment with rAAV‐sTRAIL significantly inhibited tumor formation in nude mice. Conclusion The results suggest that rAAV‐sTRAIL may be useful for local or systemic cancer gene therapy for treating TRAIL‐sensitive tumors. Copyright © 2005 John Wiley & Sons, Ltd.